CEGIR OMEGA Web Text Version 1: April 14, 2015

CEGIR OMEGA Study for Patients with Eosinophilic Esophagitis (EoE), Eosinophilic Gastritis (EG), and Eosinophilic Colitis (EC)

What is the purpose of this study?

The purpose of this observational research study is to find the best measures to define how well a person with eosinophilic disorder is doing. People with EoE, EG, and EC normally undergo endoscopy and/or colonoscopy where cells are collected for microscopic analysis. Treatments are then decided based on how the cells look. We want to see if scores on standard questionnaires can give us an idea how well the person is doing.

Who can participate?

Children and adults ages 3-65 years that have been diagnosed with EoE, EG, or EC.

What is involved?

There are multiple centers in the United States participating in this Observational Study. The Observational Study will last at least 5 years.

At your doctor visit (the doctor that treats your eosinophilic disease) if you agree to take part in this study:

- You will be asked to read and sign a consent form
- Your information related to your eosinophilic disorder will be entered into a database
- You will be asked to complete questionnaires, which will include demographic data, medication information, medical history, and laboratory data.

If you are between 5 to 18 years of age, you, as well as your parent or guardian, will be asked to complete questionnaires of quality of life and symptoms. It may take you approximately 30 to 45 minutes to complete these forms. You may complete the forms at home or during the visit.

If you would like to provide samples (blood, saliva, and/or biopsies) for the study, you will be able to do so.

You will be receiving normal standard of care (SOC) treatment from your doctor that treats your eosinophilic disorder during the study. Treatment will be the choice of your doctor.

What are the benefits?

There are no known medical benefits for taking part in this observational study. This study is not designed to treat any illness or improve any condition. The information gained in this study may be useful in helping people with eosinophilic disorders in the future.

Will I get all the facts about the study?

If you are interested in participating in this study, you will meet with a study coordinator who will explain all of the details of the study. The study coordinator will review the consent form and will

CEGIR OMEGA Web Text Version 1: April 14, 2015

be sure that all questions are answered. The consent form describes all the procedures, risks and benefits and whom to contact with questions or concerns. Study procedures will not begin until the consent has been signed by the participant.

Who should I contact for more information?

Jonathan Kuhl, BS 513-803-3078 Jonathan.kuhl@cchmc.org The Cincinnati Center for Eosinophilic Disorders Cincinnati Children's 3333 Burnet Avenue, MLC 2010 Cincinnati, OH 45229-3026

Principal Investigator: Marc E. Rothenberg, M.D., Ph.D.

Where can I find additional information? https://www.rarediseasesnetwork.org/cms/CEGIR